Capillary zone electrophoresis on-line coupled to mass spectrometry: A perspective application for clinical proteomics

Proteomics - Clinical Applications

Volumn 9, Issue 5-6, 2015, Pages 453-468

  Pejchinovski, Martin ^a   Hrnjez, Dajana ^a   Ramirez Torres, Adela ^a   Bitsika, Vasiliki ^b   Mermelekas, George ^b   Vlahou, Antonia ^b,c   Zürbig, Petra ^a   Mischak, Harald ^a,d   Metzger, Jochen ^a   Koeck, Thomas ^a  

^a MOSAIQUES DIAGNOSTICS GMBH   (Germany)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^c UNIVERSITY OF PLYMOUTH   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Biomarker; Capillary electrophoresis mass spectrometry; Clinical; Proteomics

Indexed keywords

ACUTE KIDNEY FAILURE; ANCA ASSOCIATED VASCULITIS; ATHEROSCLEROSIS; BILE DUCT CARCINOMA; BLADDER CANCER; CAPILLARY ZONE ELECTROPHORESIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DIAGNOSTIC ACCURACY; DISEASE MARKER; END STAGE RENAL DISEASE; GRAFT VERSUS HOST REACTION; HEART LEFT VENTRICLE FILLING PRESSURE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY CARCINOMA; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; MASS SPECTROMETRY; PEPTIDE ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEOMICS; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SEPARATION TECHNIQUE; URETEROPELVIC JUNCTION OBSTRUCTION; URETHRA OBSTRUCTION; URINALYSIS; VALIDITY; ANIMAL; CAPILLARY ELECTROPHORESIS; METABOLISM; NEOPLASM; PROGNOSIS; PROTEINURIA; TANDEM MASS SPECTROMETRY; URINE;

BIOLOGICAL MARKER; PROTEOME;

ANIMALS; BIOMARKERS; CARDIOVASCULAR DISEASES; ELECTROPHORESIS, CAPILLARY; GRAFT VS HOST DISEASE; HUMANS; NEOPLASMS; PROGNOSIS; PROTEINURIA; PROTEOME; PROTEOMICS; TANDEM MASS SPECTROMETRY;

EID: 84930929885     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201400113     Document Type: Review

References (124)

1. Mechref, Y., Analysis of glycans derived from glycoconjugates by capillary electrophoresis-mass spectrometry. Electrophoresis 2011, 32, 3467-3481.
2. Zhao, S. S., Zhong, X., Tie, C., Chen, D. D. et al., Capillary electrophoresis-mass spectrometry for analysis of complex samples. Proteomics. 2012, 12, 2991-3012.
3. Espada, A., Molina-Martin, M., Capillary electrophoresis and small molecule drug discovery: a perfect match? Drug Discov. Today 2012, 17, 396-404.
4. Ramautar, R., Somsen, G. W., deJong, G. J., CE-MS for metabolomics: developments and applications in the period 2010-2012. Electrophoresis 2013, 34, 86-98.
5. Boudonck, K. J., Mitchell, M. W., Nemet, L., Keresztes, L. et al., Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicol. Pathol. 2009, 37, 280-292.
6. Bonne, N. J., Wong, D. T., Salivary biomarker development using genomic, proteomic and metabolomic approaches. Genome Med. 2012, 4, 82-94.
7. Ito, E., Nakajima, K., Waki, H., Miseki, K. et al., Structural characterization of pyridylaminated oligosaccharides derived from neutral glycosphingolipids by high-sensitivity capillary electrophoresis-mass spectrometry. Anal. Chem. 2013, 85, 7859-7865.
8. Kolch, W., Mischak, H., Pitt, A. R., The molecular make-up of a tumour: proteomics in cancer research. Clin. Sci. 2005, 108, 369-383.
9. Gowda, G. A., Zhang, S., Gu, H., Asiago, V. et al., Metabolomics-based methods for early disease diagnostics. Expert. Rev. Mol. Diagn. 2008, 8, 617-633.
10. Mischak, H., Schanstra, J. P., CE-MS in biomarker discovery, validation, and clinical application. Proteomics Clin. Appl. 2011, 5, 9-23.
11. Mischak, H., Coon, J. J., Novak, J., Weissinger, E. M. et al., Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. Mass Spectrom. Rev. 2009, 28, 703-724.
12. Theodorescu, D., Mischak, H., Mass spectrometry based proteomics in urine biomarker discovery. World J. Urol. 2007, 25, 435-443.
13. Coon, J. J., Zürbig, P., Dakna, M., Dominiczak, A. F. et al., CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin. Appl. 2008, 2, 964-973.
14. Siwy, J., Mullen, W., Golovko, I., Franke, J., Zürbig, P., Human urinary peptide database for multiple disease biomarker discovery. Proteomics Clin. Appl. 2011, 5, 367-374.
15. Decramer, S., Gonzalez de, P. A., Breuil, B., Mischak, H. et al., Urine in clinical proteomics. Mol. Cell. Proteomics 2008, 7, 1850-1862.
16. Mischak, H., Delles, C., Klein, J., Schanstra, J. P. et al., Urinary proteomics based on capillary electrophoresis-coupled mass spectrometry in kidney disease: discovery and validation of biomarkers, and clinical application. Adv. Chronic Kidney Dis. 2010, 17, 493-506.
17. Jantos-Siwy, J., Schiffer, E., Brand, K., Schumann, G. et al., Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J. Proteome Res. 2009, 8, 268-281.
18. Metzger, J., Luppa, P. B., Good, D. M., Mischak, H. et al., Adapting mass spectrometry-based platforms for clinical proteomics applications: the capillary electrophoresis coupled mass spectrometry paradigm. Crit Rev. Clin. Lab Sci. 2009, 46, 129-152.
19. Kolch, W., Neususs, C., Pelzing, M., Mischak, H. et al., Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom. Rev. 2005, 24, 959-977.
20. Mischak, H., Julian, B. A., Novak, J., High-resolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine. Proteomics Clin. Appl. 2007, 1, 792-804.
21. Chalmers, M. J., Mackay, C. L., Hendrickson, C. L., Wittke, S. et al., Combined top-down and bottom-up mass spectrometric approach to characterization of biomarkers for renal disease. Anal. Chem. 2005, 77, 7163-7171.
22. Zürbig, P., Renfrow M. B., Schiffer, E., Novak, J. et al., Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis 2006, 27, 2111-2125.
23. Klein, J., Papadopoulos, T., Mischak, H., Mullen, W. et al., Comparison of CE-MS/MS and LC-MS/MS sequencing demonstrates significant complementarity in natural peptide identification in human urine. Electrophoresis 2014, 35, 1060-1064.
24. Stalmach, A., Albalat, A., Mullen, W., Mischak, H., Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications. Electrophoresis 2013, 34, 1452-1464.
25. Desiderio, C., Rossetti, D. V., Iavarone, F., Messana, I., Castagnola, M., Capillary electrophoresis-mass spectrometry: recent trends in clinical proteomics. J. Pharm. Biomed. Anal. 2010, 53, 1161-1169.
26. Zürbig, P., Jerums, G., Hovind, P., MacIsaac, R. et al., Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes 2012, 61, 3304-3313.
27. Rossing, K., Mischak, H., Dakna, M., Zürbig, P. et al., Urinary proteomics in diabetes and CKD. J. Am. Soc. Nephrol. 2008, 19, 1283-1290.
28. Alkhalaf, A., Zürbig, P., Bakker, S. J., Bilo, H. J. et al., Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One 2010, 5, e13421.
29. Good, D. M., Zürbig, P., Argiles, A., Bauer, H. W. et al., Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol. Cell. Proteomics 2010, 9, 2424-2437.
30. Argiles, A., Siwy, J., Duranton, F., Gayrard, N. et al., CKD273, a new proteomics classifier assessing CKD and its prognosis. PLoS One 2013, 8, e62837.
31. Candiano, G., Musante, L., Bruschi, M., Petretto, A. et al., Repetitive fragmentation products of albumin and alpha1-antitrypsin in glomerular diseases associated with nephrotic syndrome. J. Am. Soc. Nephrol. 2006, 17, 3139-3148.
32. Prajczer, S., Heidenreich, U., Pfaller, W., Kotanko, P. et al., Evidence for a role of uromodulin in chronic kidney disease progression. Nephrol. Dial. Transplant. 2010, 25, 1896-1903.
33. Rossing, K., Mischak, H., Rossing, P., Schanstra, J. P. et al., The urinary proteome in diabetes and diabetes-associated complications: new ways to assess disease progression and evaluate therapy. Proteomics Clin. Appl. 2008, 2, 997-1007.
34. Candiano, G., Musante, L., Bruschi, M., Petretto, A. et al., Repetitive fragmentation products of albumin and alpha1-antitrypsin in glomerular diseases associated with nephrotic syndrome. J. Am. Soc. Nephrol. 2006, 17, 3139-3148.
35. Schanstra, J. P., Zürbig, P., Alkhalaf, A., Argiles, A. et al., Diagnosis and prediction of CKD progression by assessment of urinary peptides. J. Am. Soc. Nephrol. 2015, PMID 25589610.
36. Gu, Y. M., Thijs, L., Liu, Y. P., Zhang, Z. et al., The urinary proteome as correlate and predictor of renal function in a population study. Nephrol. Dial. Transplant. 2014, 29, 2260-2268.
37. Nkuipou-Kenfack, E., Duranton, F., Gayrard, N., Argiles, A. et al., Assessment of metabolomic and proteomic biomarkers in detection and prognosis of progression of renal function in chronic kidney disease. PLoS One. 2014, 9, e96955.
38. Andersen, S., Mischak, H., Zürbig, P., Parving, H. H., Rossing, P., Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. BMC Nephrol. 2010, 11, 29-38.
39. Delles, C., Schiffer, E., vonZur, M. C., Peter, K. et al., Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. J. Hypertens. 2010, 28, 2316-2322.
40. Roscioni, S. S., de, Z. D., Hellemons, M. E., Mischak, H. et al., A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. Diabetologia 2012, 56, 259-267.
41. Siwy, J., Schanstra, J. P., Argiles, A., Bakker, S. J. et al., Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. Nephrol. Dial. Transplant. 2014, 29, 1563-1570.
42. Haubitz, M., Good, D. M., Woywodt, A., Haller H. et al., Identification and validation of urinary biomarkers for differential diagnosis and dvaluation of therapeutic intervention in ANCA associated vasculitis. Mol. Cell. Proteomics 2009, 8, 2296-2307.
43. Rodriguez-Suarez, E., Siwy, J., Zurbig, P., Mischak, H., Urine as a source for clinical proteome analysis: from discovery to clinical application. Biochim. Biophys. Acta 2013, 1844, 884-898.
44. Julian, B. A., Wittke, S., Novak, J., Good, D. M. et al., Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases. Electrophoresis 2007, 28, 4469-4483.
45. Chang, M. Y., Ong, A. C., New treatments for autosomal dominant polycystic kidney disease. Br. J. Clin. Pharmacol. 2013, 76, 524-535.
46. Harris, P. C., Rossetti, S., Molecular diagnostics for autosomal dominant polycystic kidney disease. Nat. Rev. Nephrol. 2010, 6, 197-206.
47. Kistler, A. D., Mischak, H., Poster, D., Dakna, M. et al., Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney Int. 2009, 76, 89-96.
48. Kistler, A. D., Serra, A. L., Siwy, J., Poster, D. et al., Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study. PLoS One 2013, 8, e53016.
49. Kistler, A. D., Mischak, H., Poster, D., Dakna, M. et al., Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney Int. 2009, 76, 89-96.
50. Yohannes, S., Chawla, L. S., Evolving practices in the management of acute kidney injury in the ICU (Intensive Care Unit). Clin. Nephrol. 2009, 71, 602-607.
51. Ricci, Z., Ronco, C., Today's approach to the critically ill patient with acute kidney injury. Blood Purif. 2009, 27, 127-134.
52. Koyner, J. L., Vaidya, V. S., Bennett, M. R., Ma, Q. et al., Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. Clin. J. Am. Soc. Nephrol. 2010, 5, 2154-2165.
53. Metzger, J., Kirsch, T., Schiffer, E., Ulger, P. et al., Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury. Kidney Int. 2010, 78, 1252-1262.
54. Lebeau, C., Debelle, F. D., Arlt, V. M., Pozdzik, A. et al., Early proximal tubule injury in experimental aristolochic acid nephropathy: functional and histological studies. Nephrol. Dial. Transplant. 2005, 20, 2321-2332.
55. Holmes, N., Harrison, M. R., Baskin, L. S., Fetal surgery for posterior urethral valves: long-term postnatal outcomes. Pediatrics 2001, 108, E7-E14.
56. Klein, J., Lacroix, C., Caubet, C., Siwy, J. et al., Fetal urinary peptides to predict postnatal outcome of renal disease in fetuses with posterior urethral valves (PUV). Sci. Transl. Med. 2013, 5, 198ra106.
57. Decramer, S., Wittke, S., Mischak, H., Zürbig, P. et al., Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat. Med. 2006, 12, 398-400.
58. Decramer, S., Bascands, J. L., Schanstra, J. P., Non-invasive markers of ureteropelvic junction obstruction. World J. Urol. 2007, 25, 457-465.
59. drube, J., Zürbig, P., Schiffer, E., Lau, E. et al., Urinary proteome analysis identifies infants but not older children requiring pyeloplasty. Pediatr. Nephrol. 2010, 25, 1673-1678.
60. Bandin, F., Siwy, J., Breuil, B., Mischak, H. et al., Urinary proteome analysis at 5-year followup of patients with nonoperated ureteropelvic junction obstruction suggests ongoing kidney remodeling. J. Urol. 2012, 187, 1006-1011.
61. Nichols, M., Townsend, N., Scarborough, P., Rayner, M., Cardiovascular disease in Europe: epidemiological update. Eur. Heart J. 2013, 34, 3028-3034.
62. Vasan, R. S., Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006, 113, 2335-2362.
63. Sherwood, M. W., Kristin, N. L., High-sensitivity troponin assays: evidence, indications, and reasonable use. J. Am. Heart Assoc. 2014, 3, e000403.
64. Troughton, R., Michael, F. G., Januzzi, J. L., Jr., Natriuretic peptide-guided heart failure management. Eur. Heart J 2014, 35, 16-24.
65. Wilson, P. W., Progressing from risk factors to omics. Circ. Cardiovasc. Genet. 2008, 1, 141-146.
66. Balestrieri, M. L., Giovane, A., Mancini, F. P., Napoli, C., Proteomics and cardiovascular disease: an update. Curr. Med. Chem. 2008, 15, 555-572.
67. Afsar, B., Turkmen, K., Covic, A., Kanbay, M., An update on coronary artery disease and chronic kidney disease. Int. J. Nephrol. 2014, 2014, 767424.
68. Cai, Q., Mukku, V. K., Ahmad, M., Coronary artery disease in patients with chronic kidney disease: a clinical update. Curr. Cardiol. Rev. 2013, 9, 331-339.
69. Stompor, T., Coronary artery calcification in chronic kidney disease: an update. World J. Cardiol. 2014, 6, 115-129.
70. Sallee, M., Dou, L., Cerini, C., Poitevin, S. et al., The aryl hydrocarbon receptor-activating effect of uremic toxins from tryptophan metabolism: a new concept to understand cardiovascular complications of chronic kidney disease. Toxins 2014, 6, 934-949.
71. Zimmerli, L. U., Schiffer, E., Zürbig, P., Kellmann, M. et al., Urinary proteomics biomarkers in coronary artery disease. Mol. Cell. Proteomics 2008, 7, 290-298.
72. vonZur Muhlen C., Schiffer, E., Zuerbig, P., Kellmann, M. et al., Evaluation of urine proteome pattern analysis for its potential to reflect coronary artery atherosclerosis in symptomatic patients. J. Proteome. Res. 2009, 8, 335-345.
73. Korol, R. M., Canham, P. B., Liu, L., Viswanathan, K. et al., Detection of altered extracellular matrix in surface layers of unstable carotid plaque: an optical spectroscopy, birefringence and microarray genetic analysis. Photochem. Photobiol. 2011, 87, 1164-1172.
74. vonzur Muhlen, C., Schiffer, E., Sackmann, C., Zurbig, P. et al., Urine proteome analysis reflects atherosclerotic disease in an ApoE-/- mouse model and allows the discovery of new candidate biomarkers in mouse and human atherosclerosis. Mol. Cell. Proteomics 2012, 11, M111.
75. Komamura, K., Similarities and differences between the pathogenesis and pathophysiology of diastolic and systolic heart failure. Cardiol. Res. Pract. 2013, 2013, 824135.
76. Kuznetsova, T., Mischak, H., Mullen, W., Staessen, J. A., Urinary proteome analysis in hypertensive patients with left ventricular diastolic dysfunction. Eur. Heart J. 2012, 33, 2342-2350.
77. Neumann, J., Altered phosphatase activity in heart failure, influence on Ca2+ movement. Basic Res. Cardiol. 2002, 97(Suppl 1), I91-I95.
78. Zhang, Z., Staessen, J. A., Thijs, L., Gu, Y. et al., Left ventricular diastolic function in relation to the urinary proteome: a proof-of-concept study in a general population. Int. J. Cardiol. 2014, 176, 158-165.
79. Olson, J. M., Samad, B. A., Alam, M., Prognostic value of pulse-wave tissue Doppler parameters in patients with systolic heart failure. Am. J. Cardiol. 2008, 102, 722-725.
80. Kuznetsova, T., Thijs, L., Knez, J., Herbots, L. et al., Prognostic value of left ventricular diastolic dysfunction in a general population. J. Am. Heart Assoc. 2014, 3, e000789.
81. Saenger, A. K., Christenson, R. H., Stroke biomarkers: progress and challenges for diagnosis, prognosis, differentiation, and treatment. Clin. Chem. 2010, 56, 21-33.
82. Dawson, J., Walters, M., Delles, C., Mischak, H., Mullen, W., Urinary proteomics to support diagnosis of stroke. PLoS One 2012, 7, e35879.
83. Kashyap, R. S., Nayak, A. R., Deshpande, P. S., Kabra, D. et al., Inter-alpha-trypsin inhibitor heavy chain 4 is a novel marker of acute ischemic stroke. Clin. Chim. Acta 2009, 402, 160-163.
84. Feschenko, M. S., Donnet, C., Wetzel, R. K., Asinovski, N. K. et al., Phospholemman, a single-span membrane protein, is an accessory protein of Na, K-ATPase in cerebellum and choroid plexus. J. Neurosci. 2003, 23, 2161-2169.
85. Mohty, B., Mohty, M., Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update. Blood Cancer J. 2011, 1, e16.
86. Weissinger, E. M., Mullen, W., Albalat, A., Urinary proteomics employing capillary electrophoresis coupled to mass spectrometry in the monitoring of patients after stem cell transplantation. Methods Mol. Biol. 2014, 1109, 293-306.
87. Weissinger, E. M., Schiffer, E., Hertenstein, B., Ferrara, J. L. et al., Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2007, 109, 5511-5519.
88. Weissinger, E. M., Metzger, J., Dobbelstein, C., Wolff, D. et al., Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host disease after allogeneic stem cell transplantation. Leukemia 2014, 28, 842-852.
89. Meier-Kriesche, H. U., Schold, J. D., Srinivas, T. R., Kaplan, B., Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am. J. Transplant. 2004, 4, 378-383.
90. Metzger, J., Chatzikyrkou, C., Broecker, V., Schiffer, E. et al., Diagnosis of subclinical and clinical acute T-cell-mediated rejection in renal transplant patients by urinary proteome analysis. Proteomics Clin. Appl. 2011, 5, 322-333.
91. Ploeg, M., Aben, K. K., Kiemeney, L. A., The present and future burden of urinary bladder cancer in the world. World J. Urol. 2009, 27, 289-293.
92. Tyler, A., Urothelial cancers: ureter, renal pelvis, and bladder. Semin. Oncol. Nurs. 2012, 28, 154-162.
93. Latosisnka, A., Frantzi, M., Vlahou, A., Mischak, H., Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: focus on bladder cancer. Proteomics Clin. Appl. 2013, 7, 779-793.
94. Hollenbeck, B. K., Miller, D. C., Taub, D., Dunn, R. L. et al., Risk factors for adverse outcomes after transurethral resection of bladder tumors 14. Cancer 2006, 106, 1527-1535.
95. Netto, G. J., Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? Nat. Rev. Urol. 2012, 9, 41-51.
96. Wadhwa, N., Jatawa, S. K., Tiwari, A., Non-invasive urine based tests for the detection of bladder cancer. J. Clin. Pathol. 2012, 65, 970-975.
97. Rink, M., Cha, E. K., Green, D., Hansen, J. et al., Biomolecular predictors of urothelial cancer behavior and treatment outcomes. Curr. Urol. Rep. 2012, 13, 122-135.
98. Schiffer, E., Vlahou, A., Petrolekas, A., Stravodimos, K. et al., Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin. Cancer Res. 2009, 15, 4935-4943.
99. Theodorescu, D., Wittke, S., Ross, M. M., Walden, M. et al., Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol. 2006, 7, 230-240.
100. Miller, G. J., Bauer, K. A., Howarth, D. J., Cooper, J. A. et al., Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J. Thromb. Haemost. 2004, 2, 2107-2114.
101. Ahmed, I. S., Chamberlain, C., Craven, R. J., S2R(Pgrmc1): the cytochrome-related sigma-2 receptor that regulates lipid and drug metabolism and hormone signaling. Expert Opin. Drug Metab. Toxicol. 2012, 8, 361-370.
102. Huang, Y. S., Lu, H. L., Zhang, L. J., Wu, Z., Sigma-2 receptor ligands and their perspectives in cancer diagnosis and therapy. Med. Res. Rev. 2014, 34, 532-566.
103. Roche, Y., Pasquier, D., Rambeaud, J. J., Seigneurin, D., Duperray, A., Fibrinogen mediates bladder cancer cell migration in an ICAM-1-dependent pathway. Thromb. Haemost. 2003, 89, 1089-1097.
104. Szarvas, T., vom, D. F., Ergun, S., Rubben, H., Matrix metalloproteinases and their clinical relevance in urinary bladder cancer. Nat. Rev. Urol. 2011, 8, 241-254.
105. Vlahou, A., Back to the future in bladder cancer research. Expert Rev. Proteomics 2011, 8, 295-297.
106. Jemal, A., Siegel, R., Xu, J., Ward, E., Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60, 277-300.
107. Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63, 11-30.
108. Fisher, R., Gore, M., Larkin, J., Current and future systemic treatments for renal cell carcinoma. Semin. Cancer Biol. 2013, 23, 38-45.
109. Frantzi, M., Metzger, J., Banks, R. E., Husi, H. et al., Discovery and validation of urinary biomarkers for detection of renal cell carcinoma. J. Proteomics 2014, 98, 44-58.
110. Jemal, A., Siegel, R., Ward, E., Murray, T. et al., Cancer statistics, 2006. CA Cancer J. Clin. 2006, 56, 106-130.
111. Schroder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. et al., Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 2009, 360, 1320-1328.
112. Hugosson, J., Carlsson, S., Aus, G., Bergdahl, S. et al., Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010, 11, 725-732.
113. Schroder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. et al., Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 2009, 360, 1320-1328.
114. Mohammed, A. A., Biomarkers in prostate cancer: new era and prospective. Med. Oncol. 2014, 31, 140-146.
115. Theodorescu, D., Schiffer, E., Bauer, H. W., Douwes, F. et al., Discovery and validation of urinary biomarkers for prostate cancer. Proteomics Clin. Appl. 2008, 2, 556-570.
116. Schiffer, E., Bick, C., Grizelj, B., Pietzker, S., Schofer, W., Urinary proteome analysis for prostate cancer diagnosis: cost-effective application in routine clinical practice in Germany. Int. J. Urol. 2012, 19, 118-125.
117. Skipworth, J. R., Keane, M. G., Pereira, S. P., Update on the management of cholangiocarcinoma. Dig. Dis. 2014, 32, 570-578.
118. Lankisch, T. O., Metzger, J., Negm, A. A., Vobetakuhl, K. et al., Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology 2011, 53, 875-884.
119. Metzger, J., Negm, A. A., Plentz, R. R., Weismuller, T. J. et al., Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut 2012, 62, 122-130.
120. Metzger, J., Mischak, H., Manns, M. P., Lankisch, T. O., A combined bile and urine proteomic test increases diagnostic accuracy of cholangiocarcinoma in patients with biliary strictures of unknown origin. Z. Gastroenterol. 2013, 59, 38.
121. Mullen, W., Gonzalez, J., Siwy, J., Franke, J. et al., A pilot study on the effect of short-term consumption of a polyphenol rich drink on biomarkers of coronary artery disease defined by urinary proteomics. J Agric. Food Chem. 2011, 59, 12850-12857.
122. Candiano, G., Musante, L., Bruschi, M., Petretto, A. et al., Repetitive fragmentation products of albumin and alpha1-antitrypsin in glomerular diseases associated with nephrotic syndrome. J. Am. Soc. Nephrol. 2006, 17, 3139-3148.
123. Ioannidis, J. P., Khoury, M. J., Improving validation practices in "omics" research. Science 2011, 334, 1230-1232.
124. Mischak, H., Rossing, P., Proteomic biomarkers in diabetic nephropathy-reality or future promise? Nephrol. Dial. Transplant. 2010, 25, 2843-2845.